- Download PDF Copy
- View Supplier Profile
Reviewed
From Sphere BioApr 9 2025
Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis and isolation, today announced a significant expansion of its APAC distributor network. This development marks a key milestone in the Company's global commercial strategy to meet growing demand for its next-generation single-cell analysis platforms.
Related Stories
- Unleashing the Power of Microfluidic Picodroplets
- Sphere Fluidics appoints Edward Rayner as Non-Executive Director
- Sphere Fluidics appoints Dale Levitzke as Chief Executive Officer
The expansion enhances Sphere Bio's footprint across key Asian and Pacific markets, improving regional access to its innovative technologies, local support, and technical expertise. The Company has formed partnerships with five new distributors: 1st PhileKorea (South Korea), AS ONE Corporation (Japan), Decode Science (Australia and New Zealand), Everlife Research Instruments (Singapore), and Premas Life Sciences (India and Bangladesh). These new partnerships join an already robust network, including Bang Trading (Thailand), Cold Spring Biotech (Taiwan), and Gene Company (China and Hong Kong).
This strategic scale-up enhances Sphere Bio's ability to provide localized product support and increase adoption of its growing technology portfolio, including the recently launched Cyto-Mine® Chroma platform and new assay offerings. The investment in new partnerships reflects the Company's long-term commitment to serving the region and supporting local customers with in-depth expertise.
Dale Levitzke, CEO, Sphere Bio, commented: "2025 is a pivotal year as we scale to meet growing global demand and enter high-growth markets. We have partnered with best-in-class distributors to extend our reach and bring our transformative solutions to more customers worldwide. This expansion supports our mission to accelerate scientific discovery through innovation in single-cell analysis."
Our expanded distributor network and enhanced presence reflects our commitment to providing localized customer and technical support across the APAC region. These developments represent an important step in bringing our solutions closer to researchers and advancing global adoption."
Jay Manikandan, VP Commercial (APAC), Sphere Bio
Posted in: Cell Biology | Business / Finance | Device / Technology News
Comments (0)
- Download PDF Copy
- View Supplier Profile
Citations
Please use one of the following formats to cite this article in your essay, paper or report:
APA
Sphere Bio. (2025, April 09). Sphere Bio expands APAC distribution network to strengthen presence in region. News-Medical. Retrieved on April 12, 2025 from https://www.news-medical.net/news/20250409/Sphere-Bio-expands-APAC-distribution-network-to-strengthen-presence-in-region.aspx.
MLA
Sphere Bio. "Sphere Bio expands APAC distribution network to strengthen presence in region". News-Medical. 12 April 2025. <https://www.news-medical.net/news/20250409/Sphere-Bio-expands-APAC-distribution-network-to-strengthen-presence-in-region.aspx>.
Chicago
Sphere Bio. "Sphere Bio expands APAC distribution network to strengthen presence in region". News-Medical. https://www.news-medical.net/news/20250409/Sphere-Bio-expands-APAC-distribution-network-to-strengthen-presence-in-region.aspx. (accessed April 12, 2025).
Harvard
Sphere Bio. 2025. Sphere Bio expands APAC distribution network to strengthen presence in region. News-Medical, viewed 12 April 2025, https://www.news-medical.net/news/20250409/Sphere-Bio-expands-APAC-distribution-network-to-strengthen-presence-in-region.aspx.
Suggested Reading
Sphere Fluidics appoints Curtis Nicholson as Director of Sales, EMEA, to support accelerated growth in key markets
Sphere Fluidics awarded gold accreditation by investors in people
Sphere Fluidics rebrands to Sphere Bio
Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows
Sphere Fluidics strengthens global commercial teams and establishes direct sales and support channel in North America
Sphere Fluidics announces Cyto-Mine Chroma to accelerate and streamline workflows across expanded applications in biotherapeutic discovery and development
Sphere Fluidics appoints Dr. Graeme Daniels as Vice President of Sales and Marketing
Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Comments are closed
Terms
While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.
Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.
Please do not ask questions that use sensitive or confidential information.
Read the full .
